Santhera Pharmaceuticals Holding Stock Net Income
| SANN Stock | CHF 13.06 0.06 0.46% |
As of the 28th of January, Santhera Pharmaceuticals has the Risk Adjusted Performance of 0.0886, semi deviation of 2.26, and Coefficient Of Variation of 911.14. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Santhera Pharmaceuticals, as well as the relationship between them. Please validate Santhera Pharmaceuticals information ratio, treynor ratio, value at risk, as well as the relationship between the jensen alpha and maximum drawdown to decide if Santhera Pharmaceuticals is priced more or less accurately, providing market reflects its prevalent price of 13.06 per share.
Santhera Pharmaceuticals' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Santhera Pharmaceuticals' valuation are provided below:Santhera Pharmaceuticals Holding does not presently have any fundamental trend indicators for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Santhera |
Santhera Pharmaceuticals 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Santhera Pharmaceuticals' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Santhera Pharmaceuticals.
| 10/30/2025 |
| 01/28/2026 |
If you would invest 0.00 in Santhera Pharmaceuticals on October 30, 2025 and sell it all today you would earn a total of 0.00 from holding Santhera Pharmaceuticals Holding or generate 0.0% return on investment in Santhera Pharmaceuticals over 90 days. Santhera Pharmaceuticals is related to or competes with Molecular Partners, Ascom Holding, Evolva Holding, Newron Pharmaceuticals, S H, and Coltene Holding. Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and co... More
Santhera Pharmaceuticals Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Santhera Pharmaceuticals' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Santhera Pharmaceuticals Holding upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 2.51 | |||
| Information Ratio | 0.0867 | |||
| Maximum Drawdown | 18.95 | |||
| Value At Risk | (4.47) | |||
| Potential Upside | 5.79 |
Santhera Pharmaceuticals Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Santhera Pharmaceuticals' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Santhera Pharmaceuticals' standard deviation. In reality, there are many statistical measures that can use Santhera Pharmaceuticals historical prices to predict the future Santhera Pharmaceuticals' volatility.| Risk Adjusted Performance | 0.0886 | |||
| Jensen Alpha | 0.3558 | |||
| Total Risk Alpha | 0.0441 | |||
| Sortino Ratio | 0.1188 | |||
| Treynor Ratio | 2.14 |
Santhera Pharmaceuticals January 28, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0886 | |||
| Market Risk Adjusted Performance | 2.15 | |||
| Mean Deviation | 2.41 | |||
| Semi Deviation | 2.26 | |||
| Downside Deviation | 2.51 | |||
| Coefficient Of Variation | 911.14 | |||
| Standard Deviation | 3.44 | |||
| Variance | 11.84 | |||
| Information Ratio | 0.0867 | |||
| Jensen Alpha | 0.3558 | |||
| Total Risk Alpha | 0.0441 | |||
| Sortino Ratio | 0.1188 | |||
| Treynor Ratio | 2.14 | |||
| Maximum Drawdown | 18.95 | |||
| Value At Risk | (4.47) | |||
| Potential Upside | 5.79 | |||
| Downside Variance | 6.31 | |||
| Semi Variance | 5.09 | |||
| Expected Short fall | (3.01) | |||
| Skewness | 1.43 | |||
| Kurtosis | 3.74 |
Santhera Pharmaceuticals Backtested Returns
Santhera Pharmaceuticals appears to be somewhat reliable, given 3 months investment horizon. Santhera Pharmaceuticals owns Efficiency Ratio (i.e., Sharpe Ratio) of 0.13, which indicates the firm had a 0.13 % return per unit of risk over the last 3 months. We have found twenty-nine technical indicators for Santhera Pharmaceuticals Holding, which you can use to evaluate the volatility of the company. Please review Santhera Pharmaceuticals' Risk Adjusted Performance of 0.0886, coefficient of variation of 911.14, and Semi Deviation of 2.26 to confirm if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Santhera Pharmaceuticals holds a performance score of 10. The entity has a beta of 0.17, which indicates not very significant fluctuations relative to the market. As returns on the market increase, Santhera Pharmaceuticals' returns are expected to increase less than the market. However, during the bear market, the loss of holding Santhera Pharmaceuticals is expected to be smaller as well. Please check Santhera Pharmaceuticals' total risk alpha, treynor ratio, value at risk, as well as the relationship between the sortino ratio and maximum drawdown , to make a quick decision on whether Santhera Pharmaceuticals' existing price patterns will revert.
Auto-correlation | 0.13 |
Insignificant predictability
Santhera Pharmaceuticals Holding has insignificant predictability. Overlapping area represents the amount of predictability between Santhera Pharmaceuticals time series from 30th of October 2025 to 14th of December 2025 and 14th of December 2025 to 28th of January 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Santhera Pharmaceuticals price movement. The serial correlation of 0.13 indicates that less than 13.0% of current Santhera Pharmaceuticals price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.13 | |
| Spearman Rank Test | 0.37 | |
| Residual Average | 0.0 | |
| Price Variance | 0.5 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Santhera Pharmaceuticals Holding reported net income of (55.53 Million). This is 116.27% lower than that of the Healthcare sector and 179.27% lower than that of the Biotechnology industry. The net income for all Switzerland stocks is 109.72% higher than that of the company.
Santhera Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Santhera Pharmaceuticals' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Santhera Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Santhera Pharmaceuticals by comparing valuation metrics of similar companies.Santhera Pharmaceuticals is currently under evaluation in net income category among its peers.
Santhera Fundamentals
| Return On Equity | -13.16 | |||
| Return On Asset | -0.49 | |||
| Operating Margin | (386.18) % | |||
| Current Valuation | 58.16 M | |||
| Shares Outstanding | 61.81 M | |||
| Shares Owned By Insiders | 18.77 % | |||
| Shares Owned By Institutions | 3.50 % | |||
| Price To Earning | (7.01) X | |||
| Price To Book | 30.52 X | |||
| Price To Sales | 276.19 X | |||
| Revenue | (1.59 M) | |||
| Gross Profit | (5.36 M) | |||
| EBITDA | (34.57 M) | |||
| Net Income | (55.53 M) | |||
| Cash And Equivalents | 21.21 M | |||
| Cash Per Share | 2.07 X | |||
| Total Debt | 27 M | |||
| Debt To Equity | 196.00 % | |||
| Current Ratio | 2.19 X | |||
| Book Value Per Share | (0.26) X | |||
| Cash Flow From Operations | (37.36 M) | |||
| Earnings Per Share | (1.62) X | |||
| Target Price | 4.0 | |||
| Number Of Employees | 39 | |||
| Beta | 0.8 | |||
| Market Capitalization | 50.45 M | |||
| Total Asset | 91.12 M | |||
| Z Score | 0.6 | |||
| Net Asset | 91.12 M |
About Santhera Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Santhera Pharmaceuticals Holding's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Santhera Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Santhera Pharmaceuticals Holding based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| HITI | High Tide | |
| HITI | High Tide | |
| BAC | Bank of America |
Additional Tools for Santhera Stock Analysis
When running Santhera Pharmaceuticals' price analysis, check to measure Santhera Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Santhera Pharmaceuticals is operating at the current time. Most of Santhera Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Santhera Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Santhera Pharmaceuticals' price. Additionally, you may evaluate how the addition of Santhera Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.